Telomere syndrome
MONDO:0100137Accelerated aging syndromes often caused by inheritable gene mutations resulting in decreased telomere lengths.
Also known as: STS, short telomere syndrome
80 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
One pill may tame both itchy skin and stubborn liver disease
Disease control Not yet recruitingThis study tests whether upadacitinib, a drug already approved for eczema, can help people who have both atopic dermatitis (a type of eczema) with moderate to severe itching and a hard-to-treat autoimmune liver disease called cholangitis. The drug works by blocking a pathway invo…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a common liver drug replace steroids for immunotherapy side effects?
Disease control Not yet recruitingThis phase 2 trial tests whether ursodeoxycholic acid (UDCA), a drug already used for other liver conditions, can treat cholestatic hepatitis—a liver inflammation caused by immunotherapy—better than standard steroids. About 94 adults with cancer (excluding liver cancer) who devel…
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for PBC patients: phase 3 trial of saroglitazar launches
Disease control Not yet recruitingThis study tests a new drug, saroglitazar magnesium, in 89 adults with primary biliary cholangitis (PBC) who did not get enough benefit from or could not tolerate standard treatment (UDCA). The goal is to see if the drug can lower a key liver enzyme (alkaline phosphatase) to norm…
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug seladelpar tracked in Real-Life PBC patients
Disease control Not yet recruitingThis study will follow 100 adults with primary biliary cirrhosis (PBC) who are taking seladelpar in Germany and Switzerland. Researchers will collect real-world data to see if the drug helps improve liver function tests after 48 weeks. The goal is to understand how well seladelpa…
Sponsor: University of Leipzig • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare liver disease: drug aims to slow damage
Disease control Not yet recruitingThis long-term study tests whether saroglitazar magnesium can prevent serious liver complications in people with primary biliary cholangitis (PBC), a rare autoimmune liver disease. About 386 adults already on standard treatment will receive either the drug or a placebo. The goal …
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New blood test method for liver disease could make diagnosis easier
Diagnosis Not yet recruitingThis study checks if a simpler way to collect blood samples works as well as the standard method for the HepQuant DuO liver test. The test involves drinking a natural substance and taking blood samples 20 and 60 minutes later. Researchers will compare different blood collection t…
Sponsor: HepQuant, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
Could a simple nerve block transform heart surgery recovery?
Symptom relief Not yet recruitingThis study tests whether injecting a local anesthetic near the stellate ganglion in the neck, guided by ultrasound, can improve how patients feel after heart surgery. The block temporarily calms part of the nervous system, which may reduce pain, improve sleep, and lower the risk …
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New strip drug targets debilitating itch in rare liver disease
Symptom relief Not yet recruitingThis Phase 2a trial tests TH104, a nalmefene strip placed inside the cheek, for moderate to severe itching in primary biliary cholangitis (PBC). About 40 adults with PBC will receive either TH104 or a placebo to see if it safely reduces itch. The study is not yet recruiting.
Phase: PHASE2 • Sponsor: Tharimmune Inc • Aim: Symptom relief
Last updated Jun 26, 2026 15:06 UTC
-
New study tracks pregnancy risks for elafibranor users
Knowledge-focused Not yet recruitingThis study follows people who took elafibranor shortly before or during pregnancy to see if it affects the baby or mother. Researchers will collect information from medical records and safety reports over about 10 years. No extra tests or treatments are required—only routine care…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
800-Patient study aims to unlock secrets of autoimmune liver disease
Knowledge-focused Not yet recruitingThis French study will collect medical data and biological samples from 800 people with autoimmune liver diseases. Researchers hope to identify new markers that explain why some patients respond well to treatment while others do not. The goal is to better understand the immune me…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Spleen scan could spare PBC patients unnecessary scopes
Knowledge-focused Not yet recruitingThis study looks at whether measuring spleen stiffness with a simple ultrasound-like test (FibroScan) can help doctors better predict complications in people with Primary Biliary Cholangitis (PBC). Researchers will follow 125 adults already on standard treatment, adding a spleen …
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC